BioCentury | Jul 5, 2017
Clinical News

DSMC recommends continuation of Biotron's Phase II trial of BIT225 for HIV-1 infection

...Ltd. (ASX:BIT) said an independent DSMC recommended continuation of the Phase II BIT225-009 trial of BIT225...
...27 patients. The double-blind, placebo-controlled, Thai trial is evaluating once-daily 100 and 200 mg oral BIT225...
...endpoints include immune activation and pharmacokinetics. Data from the trial are expected late this quarter. BIT225...
BioCentury | Mar 24, 2014
Clinical News

BIT225: Additional Phase II data

...Phase II trial showed that all patients with HCV genotype 3 infection who received twice-daily BIT225...
...3 infection and 4 patients with HCV genotype 1a infection. Patients received twice-daily 300 mg BIT225...
...see BioCentury, Dec. 9, 2013). The company is also evaluating a 3-month dosing regimen of BIT225...
BioCentury | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

...II trial showed that all 6 patients with HCV genotype 3 infection who received twice-daily BIT225...
...3 infection and 4 patients with HCV genotype 1a infection. Patients received twice-daily 300 mg BIT225...
...Biotron plans to start a Phase II trial to evaluate a 3-month dosing regimen of BIT225...
BioCentury | Sep 2, 2013
Clinical News

BIT225: Completed Phase II enrollment

...genotype 1, 2 or 3 in an open-label, Thai Phase II trial evaluating 300 mg BIT225...
...month, Biotron will begin a Thai Phase IIb trial to evaluate a capsule formulation of BIT225...
...Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd. (ASX:BIT), North Ryde, Australia Product: BIT225...
BioCentury | Mar 25, 2013
Clinical News

BIT225: Preliminary Phase Ib/IIa data

...Phase Ib/IIa trial in 21 treatment-naïve patients with HIV infection showed that twice-daily 400 mg BIT225...
...the trial showed that BIT225 targets HIV replication in monocytes, but did not disclose details. BIT225...
...to treat patients co-infected with HIV and HCV. Biotron Ltd. (ASX:BIT), North Ryde, Australia Product: BIT225...
BioCentury | Dec 10, 2012
Clinical News

BIT225: Phase II started

...Biotron began an open-label, Thai Phase II trial to evaluate 300 mg BIT225 once daily on...
...Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd. (ASX:BIT), North Ryde, Australia Product: BIT225...
BioCentury | Jan 9, 2012
Clinical News

BIT225: Additional Phase IIa data

...IIa trial in 24 treatment-naïve patients with HCV genotype 1 infection showed that twice-daily oral BIT225...
...RNA levels (<50 IU/mL) at week 12, of 87% vs. 63% for placebo plus SOC. BIT225...
...the most common adverse event. Patients received SOC plus twice-daily 200 or 400 mg oral BIT225...
BioCentury | Oct 17, 2011
Clinical News

BIT225: Preliminary Phase IIa data

...24 treatment-naïve patients with HCV genotype 1 infection showed that 200 and 400 mg oral BIT225...
...greater reductions in HCV RNA levels vs. placebo plus SOC at day 35. Specifically, high-dose BIT225...
...IU/mL greater reduction in HCV RNA levels compared to placebo plus SOC. Data for low-dose BIT225...
BioCentury | Oct 17, 2011
Finance

Highlights of weekly biotech stock moves

...ASX:BIT) added A$0.02 (20%) to A$0.12 last week after reporting preliminary Phase IIa data showing BIT225...
BioCentury | Mar 21, 2011
Clinical News

BIT225: Phase II ongoing

...patients in a double-blind, placebo-controlled, Thai Phase II trial to evaluate 200 or 400 mg BIT225...
...SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys and Copegus. Biotron Ltd. (ASX:BIT), North Ryde, Australia Product: BIT225...
Items per page:
1 - 10 of 11